Cargando…

418. Evaluation of β-d-Glucan (BG) and Galactomannan (GM) Detection Assays in the Diagnosis of Invasive Fungal Infections in High-Risk Pediatric Cancer Patients

BACKGROUND: Diagnosing IFD in pediatric patients is challenging: cultures are often negative and diagnostic efficacy of biomarkers such as β-d-glucan assay (BG) and galactomannan assay (GM) is unclear. The 2017 International Pediatric Fever and Neutropenia Guideline Panel recommended against the use...

Descripción completa

Detalles Bibliográficos
Autores principales: Alali, Muayad, Bhagat, Palak H, Bartlett, Allison
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255462/
http://dx.doi.org/10.1093/ofid/ofy210.429
_version_ 1783373946127646720
author Alali, Muayad
Bhagat, Palak H
Bartlett, Allison
author_facet Alali, Muayad
Bhagat, Palak H
Bartlett, Allison
author_sort Alali, Muayad
collection PubMed
description BACKGROUND: Diagnosing IFD in pediatric patients is challenging: cultures are often negative and diagnostic efficacy of biomarkers such as β-d-glucan assay (BG) and galactomannan assay (GM) is unclear. The 2017 International Pediatric Fever and Neutropenia Guideline Panel recommended against the use of fungal biomarkers for the diagnosis of IFD in pediatric patients. METHODS: We conducted a retrospective chart review of pediatric oncology patients at UCM Comer Children’s Hospitals between July 2009 to December 2016 to determine the utility of BG and GM for diagnosis of IFD. Inclusion criteria: neutropenic fever (FN), high risk for IFD (fever >5 days unresponsive to antibiotics or recurrent fever with persistent neutropenia), and ≥1 fungal biomarker sent. IFD was diagnosed using EORTC/MSG criteria with patients divided to two groups: “Proven or likely” and “less likely or unlikely.” Data pertaining to possible causes of false-positive BG and GM was collected: presence of bacterial infection, receipt of immunoglobulin (IVIG), albumin or certain antibiotics (i.e., ampicillin/sulbactam or piperacillin/tazobactam) RESULTS: Of 667 FN episodes (FNEs), 116 FNEs in 74 patients were considered high-risk for IFD and had >1 biomarker sent. BG was sent on 76 FNEs and GM on 115 FNEs,. Underlying diagnoses included: Acute lymphoblastic leukemia (43 cases (37%)), acute myeloid leukemia (27 (24%)), lymphoma (12 (10%)), solid tumors (28 (24%)), others (6 (5%)). Overall, 59 (51%) cases underwent stem cell transplant. Of 15 deaths, five were related to fungal infection. Sensitivity, specificity, positive and negative predictive values for BG are 43%, 87%, 63% and 78%, respectively, and for GM 15%, 95%, 50% and 79%, respectively. False-positive BG was noted in six FNEs. False-positive GM was noted in four FNEs (2 with non-Aspergillus molds, and two patient had bacteremia. CONCLUSION: Both BG and GM have low sensitivity and positive-predictive value supporting low utility in IFD diagnosis for pediatric patients. Our study shows a false-positive BG may be as high as 250 pg/mL in the absence of clinical and radiological symptoms suggesting IFD. High specificity of the GM may be of value in diagnosing invasive Aspergillosis (IA). Novel fungal biomarkers are needed for early IFD detection to improve outcomes. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6255462
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62554622018-11-28 418. Evaluation of β-d-Glucan (BG) and Galactomannan (GM) Detection Assays in the Diagnosis of Invasive Fungal Infections in High-Risk Pediatric Cancer Patients Alali, Muayad Bhagat, Palak H Bartlett, Allison Open Forum Infect Dis Abstracts BACKGROUND: Diagnosing IFD in pediatric patients is challenging: cultures are often negative and diagnostic efficacy of biomarkers such as β-d-glucan assay (BG) and galactomannan assay (GM) is unclear. The 2017 International Pediatric Fever and Neutropenia Guideline Panel recommended against the use of fungal biomarkers for the diagnosis of IFD in pediatric patients. METHODS: We conducted a retrospective chart review of pediatric oncology patients at UCM Comer Children’s Hospitals between July 2009 to December 2016 to determine the utility of BG and GM for diagnosis of IFD. Inclusion criteria: neutropenic fever (FN), high risk for IFD (fever >5 days unresponsive to antibiotics or recurrent fever with persistent neutropenia), and ≥1 fungal biomarker sent. IFD was diagnosed using EORTC/MSG criteria with patients divided to two groups: “Proven or likely” and “less likely or unlikely.” Data pertaining to possible causes of false-positive BG and GM was collected: presence of bacterial infection, receipt of immunoglobulin (IVIG), albumin or certain antibiotics (i.e., ampicillin/sulbactam or piperacillin/tazobactam) RESULTS: Of 667 FN episodes (FNEs), 116 FNEs in 74 patients were considered high-risk for IFD and had >1 biomarker sent. BG was sent on 76 FNEs and GM on 115 FNEs,. Underlying diagnoses included: Acute lymphoblastic leukemia (43 cases (37%)), acute myeloid leukemia (27 (24%)), lymphoma (12 (10%)), solid tumors (28 (24%)), others (6 (5%)). Overall, 59 (51%) cases underwent stem cell transplant. Of 15 deaths, five were related to fungal infection. Sensitivity, specificity, positive and negative predictive values for BG are 43%, 87%, 63% and 78%, respectively, and for GM 15%, 95%, 50% and 79%, respectively. False-positive BG was noted in six FNEs. False-positive GM was noted in four FNEs (2 with non-Aspergillus molds, and two patient had bacteremia. CONCLUSION: Both BG and GM have low sensitivity and positive-predictive value supporting low utility in IFD diagnosis for pediatric patients. Our study shows a false-positive BG may be as high as 250 pg/mL in the absence of clinical and radiological symptoms suggesting IFD. High specificity of the GM may be of value in diagnosing invasive Aspergillosis (IA). Novel fungal biomarkers are needed for early IFD detection to improve outcomes. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6255462/ http://dx.doi.org/10.1093/ofid/ofy210.429 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Alali, Muayad
Bhagat, Palak H
Bartlett, Allison
418. Evaluation of β-d-Glucan (BG) and Galactomannan (GM) Detection Assays in the Diagnosis of Invasive Fungal Infections in High-Risk Pediatric Cancer Patients
title 418. Evaluation of β-d-Glucan (BG) and Galactomannan (GM) Detection Assays in the Diagnosis of Invasive Fungal Infections in High-Risk Pediatric Cancer Patients
title_full 418. Evaluation of β-d-Glucan (BG) and Galactomannan (GM) Detection Assays in the Diagnosis of Invasive Fungal Infections in High-Risk Pediatric Cancer Patients
title_fullStr 418. Evaluation of β-d-Glucan (BG) and Galactomannan (GM) Detection Assays in the Diagnosis of Invasive Fungal Infections in High-Risk Pediatric Cancer Patients
title_full_unstemmed 418. Evaluation of β-d-Glucan (BG) and Galactomannan (GM) Detection Assays in the Diagnosis of Invasive Fungal Infections in High-Risk Pediatric Cancer Patients
title_short 418. Evaluation of β-d-Glucan (BG) and Galactomannan (GM) Detection Assays in the Diagnosis of Invasive Fungal Infections in High-Risk Pediatric Cancer Patients
title_sort 418. evaluation of β-d-glucan (bg) and galactomannan (gm) detection assays in the diagnosis of invasive fungal infections in high-risk pediatric cancer patients
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255462/
http://dx.doi.org/10.1093/ofid/ofy210.429
work_keys_str_mv AT alalimuayad 418evaluationofbdglucanbgandgalactomannangmdetectionassaysinthediagnosisofinvasivefungalinfectionsinhighriskpediatriccancerpatients
AT bhagatpalakh 418evaluationofbdglucanbgandgalactomannangmdetectionassaysinthediagnosisofinvasivefungalinfectionsinhighriskpediatriccancerpatients
AT bartlettallison 418evaluationofbdglucanbgandgalactomannangmdetectionassaysinthediagnosisofinvasivefungalinfectionsinhighriskpediatriccancerpatients